Gil Blum
Needham & Company, LLC, Research Division
My name is Gil, and I’m a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today Dr. Arthur Sands, who’s President and CEO of Nurix. And as a reminder, viewers are watching and submit questions through the Ask-a-Question box. So Arthur, a little belated, but some introductory comments and maybe a quick word on the company’s platform release.
Arthur Sands
CEO, President & Director
Sure. So we’re very excited to be entering Phase III this year for — with our new — our lead agent, bexobrutideg, which is a BTK degrader being developed for CLL. In addition, we do have ambitions for its use in I&I disease, and I’m sure we’ll talk a little bit about that, so in autoimmune indications.
But all of the Bexdeg’s success through the development so far really relates to our, I think, incredible drug discovery platform in which we have identified a whole host of novel degrader — targeted protein degrader molecules against not only oncology targets, but also autoimmune targets, including STAT6 with our partnership with Gilead and IRAK4. I mean, STAT6, sorry, with Sanofi — and then IRAK4 with Gilead, which are — which is in the clinic now and STAT6 soon to be.
So we have a whole pipeline to discuss Gil. I know you’re really familiar with our story overall. We’re headquartered in the Bay Area, approximately 350 employees. And again, very exciting year to enter pivotal trials, registrational trials.
